In the meantime, H.C. Wainwright initiated its ImmunityBio Inc [IBRX] rating to a Buy in a research note published on March 06, 2025; the price target was $8. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Piper Sandler also remained covering IBRX and has decreased its forecast on May 12, 2023 with a “Neutral” recommendation from previously “an Overweight” rating. Jefferies started covering the stock on August 03, 2022. It rated IBRX as “a Buy”.
Price Performance Review of IBRX
On Monday, ImmunityBio Inc [NASDAQ:IBRX] saw its stock jump 0.77% to $2.63. Over the last five days, the stock has gained 4.78%. ImmunityBio Inc shares have risen nearly 2.73% since the year began. Nevertheless, the stocks have fallen -45.44% over the past one year. While a 52-week high of $10.53 was reached on 02/19/25, a 52-week low of $2.28 was recorded on 01/14/25. SMA at 50 days reached $2.91, while 200 days put it at $3.75.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 2.55, which if violated will result in even more drops to 2.46. On the upside, there is a resistance level at 2.75. A further resistance level may holdings at 2.86. The Relative Strength Index (RSI) on the 14-day chart is 46.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 59.12%. Stochastics %K at 42.82% indicates the stock is a holding.
How much short interest is there in ImmunityBio Inc?
A steep rise in short interest was recorded in ImmunityBio Inc stocks on 2025-04-15, growing by 7.64 million shares to a total of 67.18 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 59.54 million shares. There was a rise of 11.37%, which implies that there is a positive sentiment for the stock.
